Intra-Cellular Therapies, Inc. (ITCI)
USD 131.87
(0.0%)
USD 131.87
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -158.85 Million USD | 39.74% |
| 2022 | -262.97 Million USD | 7.72% |
| 2021 | -285.15 Million USD | -23.55% |
| 2020 | -230.7 Million USD | -50.14% |
| 2019 | -153.53 Million USD | 5.09% |
| 2018 | -161.89 Million USD | -64.18% |
| 2017 | -102.62 Million USD | 14.3% |
| 2016 | -115.12 Million USD | -8.99% |
| 2015 | -104.65 Million USD | -244.86% |
| 2014 | -30.66 Million USD | -17.05% |
| 2013 | -26.21 Million USD | -60.66% |
| 2012 | -16.31 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -20.82 Million USD | 38.69% |
| 2024 Q3 | -38.71 Million USD | -40.79% |
| 2024 Q2 | -27.59 Million USD | -32.54% |
| 2023 Q4 | -33.96 Million USD | -14.82% |
| 2023 FY | - USD | 39.74% |
| 2023 Q1 | -48.39 Million USD | -2.07% |
| 2023 Q2 | -47.17 Million USD | 2.51% |
| 2023 Q3 | -29.57 Million USD | 37.31% |
| 2022 FY | - USD | 7.72% |
| 2022 Q4 | -47.41 Million USD | 14.51% |
| 2022 Q3 | -55.45 Million USD | 36.92% |
| 2022 Q2 | -87.92 Million USD | -21.29% |
| 2022 Q1 | -72.49 Million USD | 15.71% |
| 2021 Q4 | -86 Million USD | -11.42% |
| 2021 Q3 | -77.18 Million USD | -11.84% |
| 2021 FY | - USD | -23.55% |
| 2021 Q1 | -53.09 Million USD | 13.44% |
| 2021 Q2 | -69.01 Million USD | -29.99% |
| 2020 Q1 | -48.93 Million USD | -17.16% |
| 2020 FY | - USD | -50.14% |
| 2020 Q2 | -64.74 Million USD | -32.29% |
| 2020 Q3 | -55.93 Million USD | 13.6% |
| 2020 Q4 | -61.33 Million USD | -9.65% |
| 2019 Q1 | -36.69 Million USD | 13.91% |
| 2019 Q4 | -41.76 Million USD | -15.23% |
| 2019 Q2 | -39.06 Million USD | -6.46% |
| 2019 Q3 | -36.24 Million USD | 7.22% |
| 2019 FY | - USD | 5.09% |
| 2018 Q4 | -42.62 Million USD | 1.56% |
| 2018 FY | - USD | -64.18% |
| 2018 Q3 | -43.29 Million USD | -10.81% |
| 2018 Q2 | -39.07 Million USD | -5.6% |
| 2018 Q1 | -37 Million USD | -18.34% |
| 2017 Q3 | -22.82 Million USD | -22.91% |
| 2017 Q2 | -18.56 Million USD | 32.98% |
| 2017 Q1 | -27.7 Million USD | -1.75% |
| 2017 FY | - USD | 14.3% |
| 2017 Q4 | -31.26 Million USD | -37.01% |
| 2016 Q4 | -27.22 Million USD | 7.3% |
| 2016 Q3 | -29.37 Million USD | 6.75% |
| 2016 FY | - USD | -8.99% |
| 2016 Q1 | -28.44 Million USD | 3.14% |
| 2016 Q2 | -31.49 Million USD | -10.7% |
| 2015 Q2 | -21.47 Million USD | 3.56% |
| 2015 FY | - USD | -244.86% |
| 2015 Q4 | -29.37 Million USD | 8.54% |
| 2015 Q3 | -32.11 Million USD | -49.52% |
| 2015 Q1 | -22.27 Million USD | -46.55% |
| 2014 Q4 | -15.19 Million USD | -137.12% |
| 2014 Q2 | -4.52 Million USD | 0.15% |
| 2014 Q3 | -6.4 Million USD | -41.64% |
| 2014 FY | - USD | -17.05% |
| 2014 Q1 | -4.53 Million USD | 43.4% |
| 2013 Q2 | -10.81 Thousand USD | 99.8% |
| 2013 Q3 | -4.77 Million USD | -44083.14% |
| 2013 Q1 | -5.39 Million USD | -462.93% |
| 2013 FY | - USD | -60.66% |
| 2013 Q4 | -8 Million USD | -67.53% |
| 2012 Q4 | -958.28 Thousand USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 308.32 Million USD | 151.521% |
| Embecta Corp. | 245.4 Million USD | 164.732% |
| ANI Pharmaceuticals, Inc. | 109.32 Million USD | 245.31% |
| Dynavax Technologies Corporation | 9.66 Million USD | 1743.42% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | -5.826% |
| Pacira BioSciences, Inc. | 162.89 Million USD | 197.517% |
| PainReform Ltd. | -9.56 Million USD | -1560.079% |
| Aquestive Therapeutics, Inc. | 1.18 Million USD | 13539.34% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | -4053.652% |
| SCYNEXIS, Inc. | 73.47 Million USD | 316.188% |
| China SXT Pharmaceuticals, Inc. | -2.35 Million USD | -6656.798% |
| Cosmos Health Inc. | -17.06 Million USD | -831.045% |
| Journey Medical Corporation | 1.92 Million USD | 8369.287% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | -4053.652% |
| Safety Shot Inc | -12.18 Million USD | -1203.657% |
| Alpha Teknova, Inc. | -25.53 Million USD | -522.002% |
| Bright Green Corporation | - USD | Infinity% |
| Procaps Group, S.A. | 104.02 Million USD | 252.704% |
| Theratechnologies Inc. | -10.31 Million USD | -1440.348% |
| Harrow Health, Inc. | 9.72 Million USD | 1733.786% |
| Sonoma Pharmaceuticals, Inc. | -4.52 Million USD | -3410.564% |
| Biofrontera Inc. | -18.45 Million USD | -760.852% |
| DURECT Corporation | -24.68 Million USD | -543.546% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | 261.663% |
| Cronos Group Inc. | -72.14 Million USD | -120.174% |
| OptiNose, Inc. | -15.55 Million USD | -921.366% |
| Ironwood Pharmaceuticals, Inc. | -924.86 Million USD | 82.824% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | -340.256% |
| RedHill Biopharma Ltd. | 26.26 Million USD | 704.782% |
| Organogenesis Holdings Inc. | 36.03 Million USD | 540.879% |
| Guardion Health Sciences, Inc. | -3.92 Million USD | -3949.94% |
| Cumberland Pharmaceuticals Inc. | -710.85 Thousand USD | -22246.909% |
| Radius Health, Inc. | 38.31 Million USD | 514.652% |
| Universe Pharmaceuticals INC | -3.21 Million USD | -4840.889% |
| ProPhase Labs, Inc. | -14.82 Million USD | -971.377% |
| Phibro Animal Health Corporation | 84.6 Million USD | 287.754% |
| Procaps Group S.A. | 104.02 Million USD | 252.704% |
| Alvotech | -484.86 Million USD | 67.237% |
| TherapeuticsMD, Inc. | -8.4 Million USD | -1790.882% |
| Viatris Inc. | 3.51 Billion USD | 104.517% |
| Rockwell Medical, Inc. | -4.69 Million USD | -3284.171% |
| Aytu BioPharma, Inc. | -1.01 Million USD | -15596.937% |
| SIGA Technologies, Inc. | 84.15 Million USD | 288.752% |
| Tilray Brands, Inc. | -72.84 Million USD | -118.076% |
| Lifecore Biomedical, Inc. | 812 Thousand USD | 19663.177% |
| Shineco, Inc. | -26.55 Million USD | -498.228% |
| PetIQ, Inc. | 81.48 Million USD | 294.945% |
| Regencell Bioscience Holdings Limited | -3.61 Million USD | -4291.082% |
| Incannex Healthcare Limited | -18.5 Million USD | -758.479% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 138.177% |
| Alimera Sciences, Inc. | 7.27 Million USD | 2283.246% |
| Silver Spike Investment Corp. | 7.34 Million USD | 2264.177% |
| Assertio Holdings, Inc. | -222.44 Million USD | 28.588% |
| Shuttle Pharmaceuticals Holdings, Inc. | -3.99 Million USD | -3880.631% |
| Petros Pharmaceuticals, Inc. | -4.21 Million USD | -3671.554% |
| Clever Leaves Holdings Inc. | -16.8 Million USD | -845.328% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | -693.044% |
| Avadel Pharmaceuticals plc | -149.12 Million USD | -6.523% |
| Hempacco Co., Inc. | -12.77 Million USD | -1143.636% |
| Talphera, Inc. | -9.84 Million USD | -1514.032% |
| Alvotech | -484.86 Million USD | 67.237% |
| Eagle Pharmaceuticals, Inc. | 77.5 Million USD | 304.966% |
| Lantheus Holdings, Inc. | 491 Million USD | 132.353% |
| Currenc Group, Inc. | -1.9 Million USD | -8258.159% |
| Kamada Ltd. | 21.53 Million USD | 837.685% |
| Indivior PLC | 66 Million USD | 340.686% |
| Evoke Pharma, Inc. | -7.29 Million USD | -2078.368% |
| Flora Growth Corp. | -45.87 Million USD | -246.311% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | -693.044% |
| Evolus, Inc. | -41.81 Million USD | -279.94% |
| HUTCHMED (China) Limited | 25.52 Million USD | 722.27% |
| Amphastar Pharmaceuticals, Inc. | 241.46 Million USD | 165.787% |
| Akanda Corp. | -27.73 Million USD | -472.739% |